Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.58 |
| ▸ | HRH1 | P35367 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | HTR2C | P28335 | 3/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.58 |
| ▸ | DRD3 | P35462 | 3/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.58 |
| ▸ | CNR1 | P21554 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7806943 | 0.99 | LMNA (0.59) | SLC6A4HRH1LMNAMAPTADORA3 | |
| SCHEMBL7808599 | 0.85 | SLC6A4 (0.54) | SLC6A4HRH1LMNAMAPTADORA3 | |
| Imipramine SCHEMBL4283852 | 0.82 | SLC6A4 (0.71) | SLC6A4HRH1LMNAMAPTADORA3 | |
| SCHEMBL4733904 | 0.79 | SLC6A4 (0.65) | SLC6A4HRH1LMNAMAPTADORA3 | |
| Imipramine SCHEMBL20644144 | 0.78 | SLC6A4 (0.83) | SLC6A4HRH1LMNAMAPTADORA3 | |
| SCHEMBL26967791 | 0.78 | SLC6A4 (0.69) | SLC6A4HRH1LMNAMAPTADORA3 | |
| SCHEMBL7609741 | 0.78 | SLC6A4 (0.54) | SLC6A4HRH1LMNAMAPTADORA3 | |
| SCHEMBL30542885 | 0.75 | BCHE (0.44) | LMNACHRM1CHRM2ALDH1A1KDM4E | |
| Imipramine SCHEMBL3002526 | 0.75 | SLC6A4 (0.76) | SLC6A4HRH1LMNAMAPTADORA3 | |
| Imipramine SCHEMBL3002524 | 0.75 | SLC6A4 (0.76) | SLC6A4HRH1LMNAMAPTADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| EP-0820443-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING DIABETES | NOVO NORDISK AS (DK) | 2001-09-19 | — | — | EP | claimed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | claimed |
| EP-0820443-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-01-28 | — | — | EP | claimed |
| WO-1996031481-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | claimed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | disclosed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| EP-0820443-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING DIABETES | NOVO NORDISK AS (DK) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | VEGFA, KDR, FLT4 | SLC6A4 2949/4885HRH1 1274/4885LMNA 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.